“…The number of patients under Cu therapy was 30/57 (52.6%), of which 26 (45.6%) [6,9,11,13, 16 Á20,22,27,30,32,34] underwent Cu-histidinate therapy and 4 (7.3%) other Cu formulae (Cu-SO 4 , Cu-acetate, Cu-EDTA, unspecified Cu salts) [23,24,26,31]. The age range was 1 mo Á16 y (mean 4.89/4.2 y); eight of them were deceased.…”